190 related articles for article (PubMed ID: 26757260)
1. Phase I trial outcomes in older patients with advanced solid tumours.
Khan KH; Yap TA; Ring A; Molife LR; Bodla S; Thomas K; Zivi A; Smith A; Judson I; Banerji U; de Bono JS; Kaye SB
Br J Cancer; 2016 Feb; 114(3):262-8. PubMed ID: 26757260
[TBL] [Abstract][Full Text] [Related]
2. Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
Bando H; Rubinstein L; Harris P; Yoshino T; Doi T; Ohtsu A; Welch J; Takebe N
Gastric Cancer; 2017 May; 20(3):481-488. PubMed ID: 27510411
[TBL] [Abstract][Full Text] [Related]
3. Do elderly patients benefit from enrollment into Phase I Trials?
Tai WM; Lim C; Ahmad A; Ong WS; Choo SP; Lim WT; Tan EH; Kanesvaran R; Tan DS
J Geriatr Oncol; 2015 May; 6(3):241-8. PubMed ID: 25779876
[TBL] [Abstract][Full Text] [Related]
4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
5. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Papadatos-Pastos D; Roda D; De Miguel Luken MJ; Petruckevitch A; Jalil A; Capelan M; Michalarea V; Lima J; Diamantis N; Bhosle J; Molife LR; Banerji U; de Bono JS; Popat S; O'Brien MER; Yap TA
Eur J Cancer; 2017 Apr; 75():56-62. PubMed ID: 28214659
[TBL] [Abstract][Full Text] [Related]
7. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
George A; Kristeleit R; Rafii S; Michie CO; Bowen R; Michalarea V; van Hagen T; Wong M; Rallis G; Molife LR; Lopez J; Banerji U; Banerjee SN; Gore ME; de Bono JS; Kaye SB; Yap TA
Eur J Cancer; 2017 May; 76():52-59. PubMed ID: 28273485
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
9. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.
Mahipal A; Denson AC; Djulbegovic B; Lush R; Kumar A; Juan TH; Schell MJ; Sullivan DM
Cancer Control; 2015 Apr; 22(2):235-41. PubMed ID: 26068771
[TBL] [Abstract][Full Text] [Related]
10. The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials.
Kumar R; Geuna E; Michalarea V; Guardascione M; Naumann U; Lorente D; Kaye SB; de Bono JS
Br J Cancer; 2015 Mar; 112(7):1157-65. PubMed ID: 25719834
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.
Arkenau HT; Olmos D; Ang JE; de Bono J; Judson I; Kaye S
Br J Cancer; 2008 Mar; 98(6):1029-33. PubMed ID: 18349817
[TBL] [Abstract][Full Text] [Related]
12. Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer.
Arkenau HT; Brunetto AT; Barriuso J; Olmos D; Eaton D; de Bono J; Judson I; Kaye S
Oncology; 2009; 76(3):151-6. PubMed ID: 19169046
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
Subbiah IM; Wheler JJ; Hess KR; Hong DS; Naing A; Fu S; Kurzrock R; Tsimberidou AM
Int J Cancer; 2017 Jan; 140(1):208-215. PubMed ID: 27599876
[TBL] [Abstract][Full Text] [Related]
14. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.
Garrido-Laguna I; Janku F; Falchook GS; Fu S; Hong DS; Naing A; Aaron J; Wang X; Kies M; Kurzrock R
Clin Cancer Res; 2010 Aug; 16(15):4031-7. PubMed ID: 20525754
[TBL] [Abstract][Full Text] [Related]
15. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel.
Hensing TA; Peterman AH; Schell MJ; Lee JH; Socinski MA
Cancer; 2003 Aug; 98(4):779-88. PubMed ID: 12910523
[TBL] [Abstract][Full Text] [Related]
16. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experience.
Poon DM; Chan K; Lee SH; Chan TW; Sze H; Lee EK; Lam D; Chan MF
BMC Urol; 2016 Mar; 16():12. PubMed ID: 27001043
[TBL] [Abstract][Full Text] [Related]
18. Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.
Buechel M; McGinnis A; Vesely SK; Wade KS; Moore KN; Gunderson CC
Gynecol Oncol; 2018 Apr; 149(1):28-32. PubMed ID: 29605046
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of early phase clinical trial participation for advanced sarcoma patients.
Jones RL; Olmos D; Thway K; Fisher C; Tunariu N; Postel-Vinay S; Scurr M; de Bono J; Kaye SB; Judson IR
Cancer Chemother Pharmacol; 2011 Aug; 68(2):423-9. PubMed ID: 21069341
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
